ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0635

Medical Record Natural Language Processing and Patient Biometric and Self-Reported Measures Inform an Artificial Intelligence Augmented Remote Care Management Strategy for Lupus Patients

Gerald Lushington1, Bruce Wang2, Mohan Purushothaman3, Melissa Munroe4, Vijay R. Nadipelli5, Bernard Rubin2, Jessica Crawley2, Beth Valashinas6, Reshma Khan7, Anil Warrier8, Joseph Huffstutter9, Jennifer Murphy10, Lizeth Santamaria2, Sneha Nair2, Georg Armstrong2, Sandeep Nair2, Daniele DeFreese3, Adrian Holloway3, Arif Sorathia2, Brett Adelman2, Fabricio Pautasso2 and Eldon Jupe3, 1Progentec Diagnostics, Inc, Oklahoma City, OK, 2Progentec Diagnostics, Inc., Oklahoma City, OK, 3Progentec Diagnostics, Inc., Oklahoma City, 4Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, 5GSK, Medical Evidence Generation, Philadelphia, PA, 6Physicians Alliance of Connecticut, Milford, CT, 7Palm Beach Rheumatology and Wellness Center, Jupiter, FL, 8Millennium Rheumatology, Conroe, TX, 9Arthritis Associates PLLC, Signal Mountain, TN, 10Articularis Healthcare, Summerville, SC

Meeting: ACR Convergence 2024

Keywords: Patient reported outcomes, physical examination, quality of life, sleep, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is one of several rheumatologic disorders that presents frequent healthcare challenges, particularly for socioeconomic and geographically disadvantaged patients. Due to a shortage of rheumatologists, frequent in-person clinical evaluations to optimally manage SLE can be difficult to achieve. This study seeks to determine the potential utility of patient biometric and self-reported data in combination with natural language processing (NLP) extracted medical records (MR) as surrogate measures for physician global assessment (PGA).

Methods: We report results of a prospective study at five rheumatology clinics with 45 of 50 recruited participants completing follow up for 12 months post enrollment. This crossover study introduced a biomarker and digital management platform starting in month four. For analyses, patient biometric and self-reported measures were combined with extracted MR data. Using PGA data recorded every 90 days as a training target, cross-correlation and covariance analyses were employed to identify relationships between MR data identified by NLP, patient-reported outcome surveys (PRO; completed every 90 days), and biometrics (sleep, heart rate and activity data recorded daily), Table 1. PGA scores and MR (via NLP) data were compared to identify potential medical evaluations that reflected SLE-associated physician assessments. PRO and biometric terms were compiled concurrently for inclusion in deep learning models aimed at predicting/characterizing patient outcomes. Statistical analysis, cross-validation, and computational modeling were performed using Python statistical, machine learning, and deep learning libraries.

Results: PRO composite indices for patient fatigue (FACIT) and quality of life (QOL) had moderate correlations (0.48< R< 0.60; R=Pearson product moment correlations; 95% confidence interval (CI) [0.21-0.76]) with PGA.  Among specific metrics, strong PGA correlations (R >0.80; 95% CI for R lower bound [0.66-0.89]) were established with select NLP terms reflecting possible SLE associated disease activity and co-morbidities (discussions of general abnormalities, cardiopulmonary dysfunction, concern over blood cancers), improving wake-up latency, and other improved symptoms reflected in numerous PRO impacts (drug side-effect concerns, itchy skin, morning fatigue, etc.), Fig 1. Collectively, 24 diverse metrics with statistically significant relationships to PGA trends characterized the health status of remote patients; an additional 26 terms provided plausible influences (R >0.70 vs. PGA; 95% CI for R lower bound [0.51-0.83]) for feature selection and principal component analysis that augmented AI models reflecting possible SLE-associated disease activity and co-morbidities. 

Conclusion: These results indicate the combination of biometric and PROs alongside clinical evaluation may inform a remotely administered SLE disease management program to improve continuity of care and outcomes. Additional studies are needed to determine the impact of such a management program on treatment compliance, disease activity and flare, and long-term outcomes.

Supporting image 1

Supporting image 2


Disclosures: G. Lushington: Progentec Diagnostics, Inc., 2; B. Wang: Progentec Diagnostics, Inc, 2; M. Purushothaman: Progentec Diagnostics, Inc., 3, 4, 10; M. Munroe: Progentec Diagnostics, Inc., 3, 5, 10; V. Nadipelli: GSK, 3, 11, 12, Shareholder; B. Rubin: GSK, 3, 11, 12, Shareholder, Progentec Diagnostics, Inc., 3; J. Crawley: Progentec Diagnostics, Inc., 3; B. Valashinas: Progentec Diagnostics, Inc., 12, Clinical Study Site; R. Khan: Progentec Diagnostics, Inc., 12, Clinical Study Site; A. Warrier: Progentec Diagnostics, Inc., 12, Clinical Study Site; J. Huffstutter: None; J. Murphy: Progentec Diagnostics, Inc., 12, Clinical Study Site; L. Santamaria: Progentec Diagnostics, Inc., 2; S. Nair: Progentec Diagnostics, Inc., 3; G. Armstrong: Progentec Diagnostics, Inc., 3; S. Nair: Progentec Diagnostics, Inc., 3; D. DeFreese: Progentec Diagnostics, Inc., 3; A. Holloway: Progentec Diagnostics, Inc., 3; A. Sorathia: Progentec Diagnostics, Inc., 8; B. Adelman: Progentec Diagnostics, Inc., 8; F. Pautasso: None; E. Jupe: Progentec Diagnostics, Inc., 3, 10.

To cite this abstract in AMA style:

Lushington G, Wang B, Purushothaman M, Munroe M, Nadipelli V, Rubin B, Crawley J, Valashinas B, Khan R, Warrier A, Huffstutter J, Murphy J, Santamaria L, Nair S, Armstrong G, Nair S, DeFreese D, Holloway A, Sorathia A, Adelman B, Pautasso F, Jupe E. Medical Record Natural Language Processing and Patient Biometric and Self-Reported Measures Inform an Artificial Intelligence Augmented Remote Care Management Strategy for Lupus Patients [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/medical-record-natural-language-processing-and-patient-biometric-and-self-reported-measures-inform-an-artificial-intelligence-augmented-remote-care-management-strategy-for-lupus-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/medical-record-natural-language-processing-and-patient-biometric-and-self-reported-measures-inform-an-artificial-intelligence-augmented-remote-care-management-strategy-for-lupus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology